ADPT Reports $70.9M Q1 Rev, +35% YoY, $67.1M MRD Rev +53%, $260-270M FY26 MRD Guidance, $20M Net Loss, $2.5M Adj. EBITDA Loss
Adaptive Biotechnologies Corporation Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $15.23
+4.7% in 1d after detection
Post-detection moves
1h
—
1d
+4.7%
3d
+0.2%
7d
-4.4%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS